New statins and new doses of older statins
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 3 (1) , 14-18
- https://doi.org/10.1007/s11883-001-0005-z
Abstract
The need for greater reductions in LDL cholesterol, although remaining to be proven as clinically beneficial, continues to drive the development of either higher doses of currently approved and marketed statins or the development of new, more effective agents.Keywords
This publication has 12 references indexed in Scilit:
- A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).2000
- Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cellsAtherosclerosis, 2000
- Fluvastatin extended-release formulation is effective in treating primary hypercholesterolaemiaAtherosclerosis, 2000
- Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia — Randomized double-blind, cross-over placebo controlled studyAtherosclerosis, 2000
- Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemiaAtherosclerosis, 2000
- Comparison of fluvastatin 80 mg extended-release and 40 mg immediate-release formulationsAtherosclerosis, 2000
- Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the ratAtherosclerosis, 2000
- Efficacy and safety of cerivastatin 0.8 mg versus pravastatin 40 mg for treatment of dyslipidaemiaAtherosclerosis, 2000
- Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolaemia: The Pivotal Placebo-Controlled Clinical TrialJournal of International Medical Research, 2000
- The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/DayThe American Journal of Cardiology, 1997